GlpBio

JPH203 (KYT-0353)

目录号: GC32690纯度: >98.00%同义词: KYT-0353
JPH203 (KYT-0353) 是一种选择性 L 型氨基酸转运蛋白 1 抑制剂，显着抑制 HT-29 YD-38 和白血病细胞的亮氨酸摄取和细胞生长，IC50 值分别为 0.06 μM 和 4.1 μM 。
JPH203 (KYT-0353)
Cas No.: 1037592-40-7
规格价格库存数量操作
2mg¥491.00现货
1
5mg¥777.00现货
1
10mg¥1,250.00现货
1
25mg¥2,053.00现货
1
50mg¥3,659.00现货
1
100mg¥5,712.00现货
1
电话: 400-920-5774Email: sales@glpbio.cn

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

产品描述 Description

JPH203 (KYT-0353), a selective L-type amino acid transporter 1 inhibitor, significantly inhibited leucine uptake and cell growth in HT-29 YD-38 and leukemia cells, with IC50 values of 0.06 μM and 4.1 μM, respectively[1,5].

JPH203 (KYT-0353) can up-regulate the activated forms of pro-apoptotic factors such as Bad, Bax, Bak and caspase-9 and down-regulate anti-apoptotic factors such as Bcl-2,Bcl-xl, activation of mitochondria dependent apoptotic signaling pathway JPH203 (KYT-0353), can distinguish the relative abundance of LAT1 and LAT2, and it has high selectivity for LAT1[2]. JPH203 (KYT-0353) is metabolically stable in liver microsomes of mice, rats, dogs, monkeys and humans[3]. JPH203 (KYT-0353) induced both G2/M and G0/G1 cell cycle arrest, as well as reduced the S phase accompanied by altered expression of the proteins in cell cycle progression: cyclin D1, CDK4, and CDK6[4]. Study on leukemia reported that JPH203 (KYT-0353) induced type ?? cell death, autophagy, followed by caspase-3-dependent apoptosis at 48 h after treatment[6].LAT1 inhibition by JPH203 (KYT-0353) sensitizes cancer cells to radiation by enhancing cellular senescence via mTOR downregulation[7].

In vivo model, using intravenously administered JPH203 (KYT-0353) (12.5 and 25.0 mg/kg), a statistically significant inhibition of growth of HT-29 tumors transplanted to nude mice with only a slight decrease in body weight[4].

References:
[1]: Yun DW, Lee SA, et,al. JPH203, an L-type amino acid transporter 1-selective compound, induces apoptosis of YD-38 human oral cancer cells. J Pharmacol Sci. 2014;124(2):208-17. doi: 10.1254/jphs.13154fp. Epub 2014 Feb 4. PMID: 24492461.
[2]: Choi DW, Kim DK, et,al. JPH203, a selective L-type amino acid transporter 1 inhibitor, induces mitochondria-dependent apoptosis in Saos2 human osteosarcoma cells. Korean J Physiol Pharmacol. 2017 Nov;21(6):599-607. doi: 10.4196/kjpp.2017.21.6.599. Epub 2017 Oct 30. PMID: 29200902; PMCID: PMC5709476.
[3]: Wempe MF, Rice PJ, et,al. Metabolism and pharmacokinetic studies of JPH203, an L-amino acid transporter 1 (LAT1) selective compound. Drug Metab Pharmacokinet. 2012;27(1):155-61. doi: 10.2133/dmpk.dmpk-11-rg-091. Epub 2011 Sep 13. PMID: 21914964.
[4]: Yothaisong S, Dokduang H, et,al. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment. Tumour Biol. 2017 Mar;39(3):1010428317694545. doi: 10.1177/1010428317694545. PMID: 28347255.
[5]: Oda K, Hosoda N, et,al. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci. 2010 Jan;101(1):173-9. doi: 10.1111/j.1349-7006.2009.01386.x. Epub 2009 Oct 8. PMID: 19900191.
[6]: Rosilio, C, Nebout, M,et al. L-type amino-acid transporter 1 (LAT1): a therapeutic target supporting growth and survival of T-cell lymphoblastic lymphoma/T-cell acute lymphoblastic leukemia. Leukemia 29, 1253–1266 (2015). https://doi.org/10.1038/leu.2014.338
[7]: Bo T, Kobayashi S, et,al. LAT1 inhibitor JPH203 sensitizes cancer cells to radiation by enhancing radiation-induced cellular senescence. Transl Oncol. 2021 Nov;14(11):101212. doi: 10.1016/j.tranon.2021.101212. Epub 2021 Aug 27. PMID: 34461558; PMCID: PMC8405945.

JPH203 (KYT-0353) 是一种选择性 L 型氨基酸转运蛋白 1 抑制剂，显着抑制 HT-29 YD-38 和白血病细胞的亮氨酸摄取和细胞生长，IC50 值分别为 0.06 μM 和 4.1 μM [1,5]。

JPH203 (KYT-0353) 可上调 Bad、Bax、Bak 和 caspase-9 等促凋亡因子的激活形式，下调 Bcl-2、Bcl-xl、激活线粒体依赖性凋亡信号通路 JPH203 (KYT-0353)，可区分 LAT1 和 LAT2 的相对丰度，对 LAT1[2] 具有高选择性。 JPH203 (KYT-0353) 在小鼠、大鼠、狗、猴子和人类的肝微粒体中代谢稳定[3]。 JPH203 (KYT-0353) 诱导 G2/M 和 G0/G1 细胞周期停滞，并减少 S 期，伴随着细胞周期进程中蛋白质表达的改变:细胞周期蛋白 D1、CDK4 和 CDK6[4 ]。白血病研究报道 JPH203 (KYT-0353) 诱导 ?? 型细胞死亡、自噬，并在处理后 48 h 发生 caspase-3 依赖性细胞凋亡[6]。JPH203 (KYT-0353) 抑制 LAT1 0353) 通过下调 mTOR 增强细胞衰老，使癌细胞对辐射敏感[7]。

体内模型，使用静脉内给药的 JPH203 (KYT-0353)（12.5 和 25.0 mg/kg），对移植到裸鼠的 HT-29 肿瘤的生长有统计学意义的显着抑制，体重仅略有下降[4].

实验参考方法 Experimental Reference Method

Cell experiment [1]:

Cell lines

Saos2 cells

Preparation Method

Colony formation assays were performed by seeding 300 cells/well into 6-well plates for 24 h after growth, cells were treated with 100 M JPH203 (KYT-0353) for 72 h to remove the JPH203 (KYT-0353) treatment and cultured for 10 days with fresh medium.

Reaction Conditions

Treatment with 100 µM JPH203 (KYT-0353) for 72 hours

Applications

JPH203 (KYT-0353) inhibited colony formation in Saos2 cells.
Animal experiment [2]:

Animal models

Six-week-old male athymic BALB/c nude mice

Preparation Method

Mice in treatment group were injected with JPH203 (KYT-0353) intravenously every day for 20 days.

Dosage form

6.3 mg/kg; 12.5 mg/kg; 25 mg/kg JPH203 (KYT-0353) for 20 days

Applications

JPH203 (KYT-0353) (KYT-0353) was administered intravenously daily for 20 days at three different doses starting at day 3 after the injection of cancer cells. On the days 18 and 21, JPH203 (KYT-0353) showed dose-dependent inhibition on tumor growth with significantly inhibited tumor growth in the groups of JPH203 (KYT-0353) at 12.5 mg/kg and 25 mg/kg .

References:

[1]. Choi DW, Kim DK, et,al. JPH203, a selective L-type amino acid transporter 1 inhibitor, induces mitochondria-dependent apoptosis in Saos2 human osteosarcoma cells. Korean J Physiol Pharmacol. 2017 Nov;21(6):599-607. doi: 10.4196/kjpp.2017.21.6.599. Epub 2017 Oct 30. PMID: 29200902; PMCID: PMC5709476.

[2]. Yothaisong S, Dokduang H, et,al. Inhibition of l-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment. Tumour Biol. 2017 Mar;39(3):1010428317694545. doi: 10.1177/1010428317694545. PMID: 28347255.

产品文档 Product Documents

Purity:>98.00%

化学性质Chemical Properties

CAS 号
1037592-40-7
同义词
KYT-0353
SMILES
N[C@@H](CC1=CC(Cl)=C(C(Cl)=C1)OCC2=C(OC(C3=CC=CC=C3)=N4)C4=CC(N)=C2)C(O)=O
分子式
C23H19Cl2N3O4
分子量
472.32 g/mol
溶解性
0.1N hydrochloric acid : 7.3 mg/mL (15.46 mM);Methanol : 6.4 mg/mL (13.55 mM);DMSO : ＞100mg/ml (insoluble or slightly soluble)
保存条件
Store at -20°C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
为了提高溶解度，请将管子加热至 37°C，然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备 RT，或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

g/mol